In an open-label randomized study, molnupiravir did not reduce hospitalization or death but appeared to hasten self-reported recovery.
In the phase 3 MOVe-OUT trial, molnupiravir reduced the likelihood of hospitalization or death by about 30% among high-risk unvaccinated outpatients with mild-to-moderate COVID-19. However, molnupiravir's effect in people who have received the COVID-19 vaccine remains uncertain. Now, the PANORAMIC trial in the U.K. provides some answers.
Between December 2021 and April 2022, approximately 25,000 nonhospitalized adults with COVID-19 and symptoms for ≤5 days were randomized to receive molnupiravir plus usual care or usual care alone. Participants were aged ≥50 or aged ≥18 with at least one comorbidity that placed them at high risk for severe COVID-19; overall, 94% had received ≥3 doses of a COVID-19 vaccine. The main findings were:
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)